• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of Atrial Fibrillation on Stroke-Related Healthcare Costs Stroke
Conclusion Stroke-related care for IS, HS, and TIA is costly, especially among individuals with AF. Reducing the risk of AF-related stroke is important from both clinical and economic standpoints.
Source: JAHA:Journal of the American Heart Association - November 25, 2013 Category: Cardiology Authors: Sussman, M., Menzin, J., Lin, I., Kwong, W. J., Munsell, M., Friedman, M., Selim, M. Tags: Stroke Source Type: research

Healthcare costs before and after stroke in non-valvular atrial fibrillation patients who initiated treatment with rivaroxaban or warfarin.
CONCLUSIONS: Total all-cause costs of care increased in the post-stroke period, and particularly in the patients treated with warfarin relative to those treated with rivaroxaban. The lower rate of stroke in the rivaroxaban cohort suggests that greater pre- to post-stroke cost increases result from more strokes occurring in the warfarin cohort. PMID: 33499689 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Abstract 301: Healthcare Costs Following Stroke and Major Bleeding Events in Nonvalvular Atrial Fibrillation Patients Session Title: Poster Session III
Conclusions: NVAF patients who have a stroke or MB event incur higher healthcare costs relative to patients without events. Interventions preventing stroke or MB events have the potential to reduce the healthcare burden associated NVAF.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Naccarelli, G., Stokes, M., DeLeon, A., Tate, N., Wang, R., Wang, A., Fredell, J. Tags: Session Title: Poster Session III Source Type: research

Evaluation of the Influence of Etiological Factors on the Economic Burden of Ischemic Stroke in Younger Patients in China Using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Classification.
CONCLUSIONS In the younger patient population in China, etiological factors influenced the economic burden of ischemic stroke. PMID: 30666992 [PubMed - in process]
Source: Medical Science Monitor - January 24, 2019 Category: Research Tags: Med Sci Monit Source Type: research

Impact of Atrial Fibrillation on Stroke-Related Healthcare Costs Hypertension
Conclusion Stroke-related care for IS, HS, and TIA is costly, especially among individuals with AF. Reducing the risk of AF-related stroke is important from both clinical and economic standpoints.
Source: JAHA:Journal of the American Heart Association - November 25, 2013 Category: Cardiology Authors: Sussman, M., Menzin, J., Lin, I., Kwong, W. J., Munsell, M., Friedman, M., Selim, M. Tags: Hypertension Source Type: research

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
CONCLUSIONS: The incremental healthcare costs incurred by patients with versus without stroke/SE was nearly twice as high as those of patients with versus without MB. Moreover, each additional year up to 4 years after the first event was associated with an incremental cost for patients with a stroke/SE or MB event compared to those without an event. PMID: 30939954 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 5, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review
AbstractThe aim of this study was to summarize healthcare costs incurred by patients with atrial fibrillation (AF) who developed ischaemic stroke, explore factors associated with increased cost, and highlight the importance of anticoagulation therapy for stroke prophylaxis. A systematic literature search of PubMed, EMBASE, Web of Science, and the health economic evaluation database was conducted up to December 2015. Studies focused on the cost and/or resource utilization of ischaemic stroke in patients with AF were included. Reported costs were converted to international dollars (I$) and adjusted to 2015 values. Alongside ...
Source: Europace - May 21, 2016 Category: Cardiology Source Type: research

The incidence of stroke in patients with early echocardiography after acute myocardial infarction
AbstractLeft ventricular (LV) thrombus formation after ST-elevation myocardial infarction (STEMI) increases the risk of stroke. In our center, most echocardiograms are performed within 2  days post-STEMI. However, LV thrombi often become visible later. We assessed the 1-year incidence of stroke in patients without LV thrombus on echocardiography performed early (1–2 days) vs. later (day ≥ 3) post-STEMI. This retrospective observational study included 416 patients with acut e STEMI. Patients with atrial fibrillation were excluded. All patients underwent echocardiography during admission. Patients with stroke withi...
Source: The International Journal of Cardiovascular Imaging - July 12, 2021 Category: Radiology Source Type: research

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Car...
Source: Europace - June 26, 2015 Category: Cardiology Authors: Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., Hobbs, F. D. R., on behalf of the Writing Committee of the Action for Stroke Prevention alliance, on behalf of the Writing Committee of the Action for Stroke Prevention alliance, John Camm, Pinto, H Tags: REVIEW Source Type: research

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
ConclusionPatients receiving dabigatran had significantly lower total all-cause, inpatient, and outpatient costs but higher pharmacy costs than those receiving warfarin. In addition, stroke-specific total and outpatient costs and bleed-specific total and inpatient costs were significantly lower in dabigatran users compared with warfarin users.
Source: American Journal of Cardiovascular Drugs - August 9, 2017 Category: Cardiology Source Type: research

An electronic decision support tool for Stroke Prevention in Atrial Fibrillation (SPAF): An integrated primary-tertiary care model of care. (S47.001)
CONCLUSIONS: Given that the existing technology base is well established nationwide, it is expected that this could become a national model which would have significant benefits for patient care and healthcare costs across the country.Disclosure: Dr. Jolliffe has nothing to disclose. Dr. Rosemergy has nothing to disclose. Dr. Lanford has nothing to disclose. Dr. Abernethy has nothing to disclose. Dr. Ranta has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jolliffe, E., Rosemergy, I., Lanford, J., Abernethy, D., Ranta, A. Tags: Cerebrovascular Disease and Interventional Neurology Source Type: research

Stroke prevention for patients with atrial fibrillation: improving but not perfect yet
Atrial fibrillation (AF) is the most common cardiac rhythm disorder1 and one of the most important risk factors for stroke, particularly in the elderly. Stroke-related AF is associated with significant morbidity, mortality and healthcare costs.2 Although we have abundant evidence from randomised trials that anticoagulation, and to a lesser extent antiplatelet therapy, is highly efficacious in preventing stroke in patients with AF, these therapies remain underused, especially in older patients. With an ageing population and an AF prevalence that is rapidly rising,1 a better understanding of the stroke prevention practices i...
Source: Heart - July 19, 2013 Category: Cardiology Authors: Sandhu, R. K., McAlister, F. A. Tags: Health policy, Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Implications of stroke and bleeding risk-scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
CONCLUSION: NVAF patients accrue variable healthcare costs. Stroke and bleeding risk should be taken into account during the creation of NVAF payment bundles. PMID: 29164990 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 23, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda
Atrial fibrillation (AF) is the most common heart arrhythmia. Untreated AF incurs a considerable burden of stroke and associated healthcare costs. Asians have AF risk factors similar to Caucasians and similarly increased risk of AF-related stroke; however, with a vast and rapidly aging population, Asia bears a disproportionately large disease burden. Urgent action is warranted to avert this potential health crisis. Antithrombotic therapy with oral anticoagulants is the most effective means of preventing stroke in AF and is a particular priority in Asia given the increasing disease burden.
Source: International Journal of Cardiology - March 26, 2015 Category: Cardiology Authors: Chen-Huan Chen, Mien-Cheng Chen, Harry Gibbs, Sun U. Kwon, Sidney Lo, Young Keun On, Azhari Rosman, Nijasri C. Suwanwela, Ru San Tan, Louie S. Tirador, Andreas Zirlik Tags: Review Source Type: research

Medicare beneficiary out-of-pocket spending for stroke prevention in non-valvular Atrial Fibrillation: a budget analysis
Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: S. Armstrong, S.L. Amorosi, G. Erickson, P. Patel, K. Stein Source Type: research

Pages: 1  2  3